-+ 0.00%
-+ 0.00%
-+ 0.00%

Clarity Pharmaceuticals completes patient follow-ups in Phase III AMPLIFY prostate cancer imaging trial

PUBT·11/18/2026 22:22:04
Listen to the news
Clarity Pharmaceuticals completes patient follow-ups in Phase III AMPLIFY prostate cancer imaging trial
  • Clarity Pharmaceuticals completed all patient follow-up assessments in its Phase III AMPLIFY trial of prostate cancer imaging agent 64Cu-SAR-bisPSMA.
  • The trial evaluates the agent’s ability to detect recurrent prostate cancer following initial treatment.
  • Topline results from AMPLIFY and the separate Phase III CLARIFY trial are expected in the first half of 2027.
  • Final results are intended to support US FDA approval applications; the agent has received Breakthrough Therapy designation for imaging recurrent prostate cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief on November 19, 2026, and is solely responsible for the information contained therein.